StockNews.com Initiates Coverage on Ayala Pharmaceuticals (NASDAQ:ADXS)

Analysts at StockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS) in a research report issued on Sunday. The brokerage set a “sell” rating on the stock.

Ayala Pharmaceuticals Price Performance

Ayala Pharmaceuticals stock opened at $0.02 on Friday. The firm has a market cap of $852,600.00, a P/E ratio of 0.00 and a beta of 1.51. The business has a fifty day moving average of $0.06 and a two-hundred day moving average of $0.32. Ayala Pharmaceuticals has a twelve month low of $0.00 and a twelve month high of $1.49.

Ayala Pharmaceuticals Company Profile

Ayala Pharmaceuticals, Inc, a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia.